Monday, February 27, 2017

Drugs in Clinical Pipeline: AL-3778 I Treatment for Hepatitis B Virus (HBV) | Antivirals Agents

AL-3778 (also known as ALS-003778; JNJ-63595948; NVR-1221; NVR-3-778) is an experimental drug being developed by Alios BioPharma, Inc. to treat Hepatitis B virus infection. Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection.

Treatment for Hepatitis B Virus (HBV)
A New Drug for the Treatment for Hepatitis B Virus (HBV)

Friday, February 24, 2017

Drugs in Clinical Pipeline: MCLA-117 | CLEC12AxCD3 Bispecific Immunoglobulin G (IgG) | Bispecific Antibody I Treatment for Acute Myleoid Leukemia (AML)

MCLA-117 is a full length human CLEC12AxCD3 bispecific immunoglobulin G (IgG) that incorporates CH2 region amino acid substitutions to abrogate Fcγ receptor and C1q interactions while retaining its binding to FcRn. MCLA-117 binds to CD3, a cell-surface molecule present on all T cells, and CLEC12A, a cell surface molecule present on Acute Myleoid Leukemia (AML) cells and stem cells. MCLA-117 is designed to recruit and activate T-cells to kill CLEC12A-expressing AML tumor cells and stem cells, which may prevent recurrence of tumors. MCLA-117 redirects patient's cytotoxic T cells to induce AML tumor lysis.

Tuesday, February 21, 2017

Drugs in Clinical Pipeline: SC-006 | Treatment of Colorectal Cancer (CRC)

SC-006 is an experimental drug being developed by AbbVie in collaboration with Stemcentrx, for treating patients with advanced colorectal cancer (CRC).

Treatment of Colorectal Cancer
New Drug for Treating Colorectal Cancer
AbbVie, a global biopharmaceutical company, announced in April 2016 that it will acquire Stemcentrx to further boost it’s oncology pipeline. SC-006 is a fruit of the merger. Though the mechanism of action is not revealed, it could be directed against DLL3 (delta-like protein 3) like SC-002.